{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:48:36Z","timestamp":1767134916471,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd006049","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,1,9]],"date-time":"2017-01-09T00:00:00Z","timestamp":1483920000000}}],"reference-count":33,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006049.pub2","type":"journal-article","created":{"date-parts":[[2017,1,9]],"date-time":"2017-01-09T12:42:38Z","timestamp":1483965758000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Gamma aminobutyric acid (GABA) modulators for amyotrophic lateral sclerosis\/motor neuron disease"],"prefix":"10.1002","volume":"2017","author":[{"given":"Andrea","family":"Diana","sequence":"first","affiliation":[{"name":"University of Cagliari; Department of Biomedical Sciences; Citta Universitaria di Monserrato (Cagliari) Monserrato (Cagliari) Italy 09042"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Pillai","sequence":"additional","affiliation":[{"name":"University of Cagliari; Department of Biomedical Sciences; Citta Universitaria di Monserrato (Cagliari) Monserrato (Cagliari) Italy 09042"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Bongioanni","sequence":"additional","affiliation":[{"name":"University of Pisa; Neurorehabilitation Unit, Department of Neuroscience; Via Paradisa, 2 Pisa Italy 56100"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aidan G","family":"O'Keeffe","sequence":"additional","affiliation":[{"name":"University College London; Department of Statistical Science; 1-19 Torrington Place London UK WC1E 6BT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert G","family":"Miller","sequence":"additional","affiliation":[{"name":"California Pacific Medical Center; Forbes Norris ALS Research Center; 2324 Sacramento Street, Suite 150 San Francisco USA 94115"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan H","family":"Moore","sequence":"additional","affiliation":[{"name":"California Pacific Medical Center; Research Institute; 475 Brannan St Suite 220 San Francisco CA USA 94107"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,1,9]]},"reference":[{"issue":"6","key":"10.1002\/14651858.CD006049.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1212\/WNL.47.6.1383","article-title":"Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. WALS Study Group. Western Amyotrophic Lateral Sclerosis Study Group","volume":"47","author":"Miller","year":"1996","journal-title":"Neurology"},{"issue":"7","key":"10.1002\/14651858.CD006049.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1212\/WNL.56.7.843","article-title":"Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis","volume":"56","author":"Miller","year":"2001","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD006049.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1212\/WNL.54.1.58","article-title":"Pharmacologic reversal of cortical hyperexcitability in patients with ALS","volume":"54","author":"Caramia","year":"2000","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD006049.pub2-BIB0004|cit4","first-page":"476","article-title":"Gabapentin therapy for amyotrophic lateral sclerosis: lack of improvement in neuronal integrity shown by MR spectroscopy","volume":"24","author":"Kalra","year":"2003","journal-title":"American Journal of Neuroradiology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006049.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/S0022-510X(98)00199-3","article-title":"The natural history and the effects of gabapentin in amyotrophic lateral sclerosis","volume":"160","author":"Mazzini","year":"1998","journal-title":"Journal of the Neurological Sciences"},{"issue":"11","key":"10.1002\/14651858.CD006049.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/archneur.1979.00500470085019","article-title":"Trial of baclofen in amyotrophic lateral sclerosis","volume":"36","author":"Norris","year":"1979","journal-title":"Archives of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD006049.pub2-BIB0007|cit7","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004156.pub4","article-title":"Treatment for spasticity in amyotrophic lateral sclerosis\/motor neuron disease","author":"Ashworth","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD006049.pub2-BIB0008|cit8","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004157.pub2","article-title":"Treatment for cramps in amyotrophic lateral sclerosis\/motor neuron disease","author":"Baldinger","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD006049.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1080\/146608200300079536","article-title":"El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis","volume":"1","author":"Brooks","year":"2000","journal-title":"Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders"},{"issue":"5","key":"10.1002\/14651858.CD006049.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S0968-0896(99)00023-1","article-title":"An in vitro investigation into conformational aspects of gabapentin","volume":"7","author":"Bryans","year":"1999","journal-title":"Bioorganic and Medicinal Chemistry"},{"issue":"1-2","key":"10.1002\/14651858.CD006049.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0022-510X(99)00210-5","article-title":"The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III)","volume":"169","author":"Cedarbaum","year":"1999","journal-title":"Journal of Neurological Sciences"},{"issue":"2","key":"10.1002\/14651858.CD006049.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000351153","article-title":"Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature","volume":"41","author":"Chi\u00f2","year":"2013","journal-title":"Neuroepidemiology"},{"issue":"2","key":"10.1002\/14651858.CD006049.pub2-BIB0013|cit13","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006049","article-title":"Gamma aminobutyric acid (GABA) modulators for amyotrophic lateral sclerosis\/motor neuron disease","author":"Diana","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD006049.pub2-BIB0014|cit14","unstructured":"Jan Brozek, Andrew Oxman, Holger Sch\u00fcnemann GRADEpro 2008"},{"key":"10.1002\/14651858.CD006049.pub2-BIB0015|cit15","unstructured":"Higgins JPT Altman DG Sterne JAC Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"1","key":"10.1002\/14651858.CD006049.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1034\/j.1600-0404.2002.00149.x","article-title":"Motor unit hyperexcitability in amyotrophic lateral sclerosis vs amino acids acting as neurotransmitters","volume":"106","author":"Kostera-Pruszczyk","year":"2002","journal-title":"Acta Neurologica Scandinavica"},{"issue":"11","key":"10.1002\/14651858.CD006049.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1093\/brain\/123.11.2289","article-title":"Extramotor involvement in ALS: PET studies with GABA(A) ligand [(11)C]flumazenil","volume":"123","author":"Lloyd","year":"2000","journal-title":"Brain"},{"issue":"1","key":"10.1002\/14651858.CD006049.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1600-0404.1999.tb00717.x","article-title":"Amino acids acting as transmitters in amyotrophic lateral sclerosis (ALS)","volume":"100","author":"Niebroj-Dobosz","year":"1999","journal-title":"Acta Neurologica Scandinavica"},{"issue":"2-3","key":"10.1002\/14651858.CD006049.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ejphar.2004.05.029","article-title":"Gabapentin activates presynaptic GABAB heteroreceptors in rat cortical slices","volume":"495","author":"Parker","year":"2004","journal-title":"European Journal of Pharmacology"},{"issue":"24","key":"10.1002\/14651858.CD006049.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"2815-34. Erratu","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"issue":"10","key":"10.1002\/14651858.CD006049.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1093\/jnen\/62.10.1041","article-title":"Distribution of GABAA receptor mRNA in the motor cortex of ALS patients","volume":"62","author":"Petri","year":"2003","journal-title":"Journal of Neuropathology and Experimental Neurology"},{"issue":"5","key":"10.1002\/14651858.CD006049.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/ana.410220503","article-title":"Abnormal glutamate metabolism in amyotrophic lateral sclerosis","volume":"22","author":"Plaitakis","year":"1987","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD006049.pub2-BIB0023|cit23","unstructured":"Rand Corporation 36-Item Short Form Survey (SF-36) www.rand.org\/health\/surveys_tools\/mos\/36-item-short-form.html"},{"issue":"1","key":"10.1002\/14651858.CD006049.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.tins.2003.11.001","article-title":"Excitotoxic and oxidative cross-talk between motor neurons and glia in ALS pathogenesis","volume":"27","author":"Rao","year":"2004","journal-title":"Trends in Neurosciences"},{"key":"10.1002\/14651858.CD006049.pub2-BIB0025|cit25","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"2","key":"10.1002\/14651858.CD006049.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/ana.410300223","article-title":"Excitatory amino acids in amyotrophic lateral sclerosis: an update","volume":"30","author":"Rothstein","year":"1991","journal-title":"Annals of Neurology"},{"issue":"3","key":"10.1002\/14651858.CD006049.pub2-BIB0027|cit27","first-page":"261","article-title":"Antiepileptics from gamma-aminobutyric acid","volume":"44","author":"Satzinger","year":"1994","journal-title":"Arzneimittel-Forschung"},{"issue":"2","key":"10.1002\/14651858.CD006049.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1006\/neur.1995.0026","article-title":"CSF and plasma amino acid levels in motor neuron disease: elevation of CSF glutamate in a subset of patients","volume":"4","author":"Shaw","year":"1995","journal-title":"Neurodegeneration"},{"issue":"2","key":"10.1002\/14651858.CD006049.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0022-510X(01)00661-X","article-title":"Glutamate levels in cerebrospinal fluid in amyotrophic lateral sclerosis: a reappraisal using a new HPLC method with coulometric detection in a large cohort of patients","volume":"193","author":"Spreux-Varoquaux","year":"2002","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1002\/14651858.CD006049.pub2-BIB0030|cit30","unstructured":"StataCorp Stata Statistical Software 2009"},{"issue":"6 Suppl 5","key":"10.1002\/14651858.CD006049.pub2-BIB0031|cit31","first-page":"S10-6; discussi","article-title":"Emerging perspectives on the mechanism of action of gabapentin","volume":"44","author":"Taylor","year":"1994","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD006049.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0920-1211(97)00084-3","article-title":"A summary of mechanistic hypotheses of gabapentin pharmacology","volume":"29","author":"Taylor","year":"1998","journal-title":"Epilepsy Research"},{"issue":"4","key":"10.1002\/14651858.CD006049.pub2-BIB0033|cit33","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006282.pub4","article-title":"Drug treatment for spinal muscular atrophy types II and III","author":"Wadman","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD006049.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T00:17:59Z","timestamp":1695169079000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD006049.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Neuromuscular Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,1,9]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006049.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,9]]}}}